Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Nov;66(5):827–832. doi: 10.1038/bjc.1992.368

Potent antitumour activity of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice.

K Akamatsu 1, K Endo 1, T Matsumoto 1, K Kamisango 1, K Morikawa 1, M Koizumi 1, K Koizumi 1
PMCID: PMC1977960  PMID: 1419625

Abstract

The time dependency of the antitumour activity of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato++ +)platinum(II) monohydrate (DWA2114R) was examined in mice inoculated i.p. with 10(5) mouse L1210 leukaemia cells. The increase in life span was greater in mice treated with 72 mg kg-1 DWA2114R on the 6th day following tumour inoculation than in mice treated at earlier times. Such superior effects against advanced L1210 were also seen with cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) but not seen with the parent compound, cis-diamminedichloroplatinum(II) (CDDP) or other antitumour agents devoid of platinum. After the injection of DWA2114R on day 6, most of the ascites tumour cells accumulated in the S and G2/M phases of the cell cycle and the total cell number markedly decreased from 10(8) to less than 10(6). On the other hand, only a temporary G1 arrest and a less than 50% reduction of the cell number were induced after a similar treatment on day 3. Interestingly, the superiority of DWA2114R for advanced L1210 was lost in athymic nude mice and mice depleted of T cells by anti-thymocyte antisera. In addition, mice cured of advanced L1210 specifically rejected re-inoculated L1210 cells. These results indicate that the superior antitumour activity against advanced L1210 is unique to DWA2114R among the agents tested (except for CBDCA) and is caused by both an increased drug susceptibility of tumour cells and a drug-induced antitumour effect mediated by T cells of the host mice.

Full text

PDF
827

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akamatsu K., Endo K., Matsumoto T., Morikawa K., Koizumi M., Mitsui H., Koizumi K. In vitro antitumor mechanism of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++) platinum(II). Anticancer Res. 1991 Jan-Feb;11(1):151–155. [PubMed] [Google Scholar]
  2. Bhuyan B. K., Fraser T. J., Day K. J. Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells. Cancer Res. 1977 Apr;37(4):1057–1063. [PubMed] [Google Scholar]
  3. Bruce W. R., Meeker B. E., Valeriote F. A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst. 1966 Aug;37(2):233–245. [PubMed] [Google Scholar]
  4. Endo K., Akamatsu K., Matsumoto T., Morikawa K., Koizumi M., Mitsui H., Koizumi K. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice. Anticancer Res. 1992 Jan-Feb;12(1):49–58. [PubMed] [Google Scholar]
  5. Habu S., Fukui H., Shimamura K., Kasai M., Nagai Y., Okumura K., Tamaoki N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981 Jul;127(1):34–38. [PubMed] [Google Scholar]
  6. Kataoka T., Matsuura N., Oh-hashi F., Suhara Y. Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors. Cancer Res. 1985 Aug;45(8):3548–3553. [PubMed] [Google Scholar]
  7. Kleinerman E. S., Zwelling L. A., Muchmore A. V. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum(II). Cancer Res. 1980 Sep;40(9):3099–3102. [PubMed] [Google Scholar]
  8. Kociba R. J., Sleight S. D., Rosenberg B. Inhibition of Dunning asc itic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep. 1970 Oct;54(5):325–328. [PubMed] [Google Scholar]
  9. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  10. Mally M. B., Taylor R. C., Callewaert D. M. Effects of platinum antitumor agents on in vitro assays of human antitumor immunity. I. Effects of cis-[pt (NH3)2Cl2] on the mixed lymphocyte tumor assay. Chemotherapy. 1979;25(2):117–128. doi: 10.1159/000237831. [DOI] [PubMed] [Google Scholar]
  11. Mally M. B., Taylor R. C., Callewaert D. M. Effects of platinum antitumor agents on in vitro assays of human antitumor immunity. II. Effects of cis-[Pt(NH3)2Cl2] on spontaneous cell-mediated cytotoxicity. Chemotherapy. 1980;26(1):1–6. doi: 10.1159/000237876. [DOI] [PubMed] [Google Scholar]
  12. Matsumoto T., Endoh K., Akamatsu K., Kamisango K., Mitsui H., Koizumi K., Morikawa K., Koizumi M., Matsuno T. Comparison of the antitumour effects and nephrotoxicity-inducing activities of two new platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)-platinum (II) monohydrate, and its enantiomeric isomer. Br J Cancer. 1991 Jul;64(1):41–46. doi: 10.1038/bjc.1991.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mokyr M. B., Dray S. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Invest. 1987;5(1):31–38. doi: 10.3109/07357908709020304. [DOI] [PubMed] [Google Scholar]
  14. Morikawa K., Honda M., Endoh K., Matsumoto T., Akamatsu K., Mitsui H., Koizumi M. Synthesis and antitumor activities of platinum complexes of unsymmetrical alicyclic diamines as carrier ligands. J Pharm Sci. 1990 Aug;79(8):750–753. doi: 10.1002/jps.2600790819. [DOI] [PubMed] [Google Scholar]
  15. Prestayko A. W., D'Aoust J. C., Issell B. F., Crooke S. T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 1979 Mar;6(1):17–39. doi: 10.1016/s0305-7372(79)80057-2. [DOI] [PubMed] [Google Scholar]
  16. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H. Platinum compounds: a new class of potent antitumour agents. Nature. 1969 Apr 26;222(5191):385–386. doi: 10.1038/222385a0. [DOI] [PubMed] [Google Scholar]
  17. Sarna S., Sodhi A. Chemo-immunotherapeutical studies on a fibrosarcoma with cis-dichlorodiammine platinum (II). Indian J Exp Biol. 1978 Dec;16(12):1236–1239. [PubMed] [Google Scholar]
  18. Stark J. J., Howel S. B. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther. 1978 Apr;23(4):461–466. doi: 10.1002/cpt1978234461. [DOI] [PubMed] [Google Scholar]
  19. Van Putten L. M., Lelieveld P., Kram-Idsenga L. K. Cell-cycle specificity and therapeutic effectiveness of cytostatic agents. Cancer Chemother Rep. 1972 Dec;56(6):691–700. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES